- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05224804
Pharmacists' Knowledge and Attitudes About ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals
Study Overview
Detailed Description
The practice and science of pharmacovigilance is described as the gathering, identification, monitoring, assessment, and prevention of adverse medication effects using pharmaceutical products. The term "pharmacovigilance" comes from the Greek words pharmakon (drug) and vigilare (vigilance) (monitor or keep an eye on). Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as "the science and practices relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems". PV assesses the risk-benefit profile of medicines in order to improve patient safety. As a result, adverse drug reaction (ADR) reporting is the bedrock of any PV system, and early detection and reporting of ADRs to regional or national drug-regulatory bodies is important.
ADRs are defined by the World Health Organization as an unpleasant and unexpected response to a medicine that occurs at levels usually employed in man for the prevention, diagnosis, or therapy of disease, or for the alteration of physiological function". Adverse drug reactions (ADRs) are major public health issues that have been linked to longer hospital stays and higher therapeutic costs. According to recent systematic reviews and meta-analyses of observational research, the rate of hospital admissions linked to ADRs is between 3-5 percent.
A number of factors have been linked to HCPs, particularly pharmacists, reporting ADRs. Several studies have indicated reasons for not reporting observed ADRs, and pharmacists have been polled to determine the most important facilitators and barriers to spontaneous reporting. The seven deadly sins were coined by Inman and later defined by Lopez-Gonzalez et al., into professional and personal traits, as well as knowledge and attitudes toward reporting. Pharmacists from throughout the world have highlighted a number of barriers to reporting ADRs, including a lack of time, the inability to correlate an adverse event (AE) to a specific medicine, and the absence of readily available reporting forms . It has also emphasized the necessity of educational measures to encourage ADR reporting, such as awareness lectures and workshops.
Egypt joined the WHO International Program for Drug Monitoring in 2001, but no concrete actions were done until 2009, when the Egyptian Pharmacovigilance Center was established (EPVC). Receiving ADR reports, detecting safety signals, sending frequent newsletters with pharmacovigilance (PV)-related updates, and conducting awareness training are only a few of EPVC's responsibilities.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Fayoum, Egypt, 63111
- Marwa Kamal Ahmed Tolba
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pharmacist graduates
Exclusion Criteria:
undergrauate pharmacist
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacists' Knowledge and Attitudes about ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals
Time Frame: 1 year and 4 month to collect data.
|
The majority of pharmacists was knowledgeable about pharmacovigilance and had a favourable attitude toward ADR reporting.
There are several variables that discourage pharmacists from reporting suspected ADRs, including the belief that there is no advantage to reporting, the presence of administrative barriers, the lack of availability of the ADR reporting form, and the lack of encouragement from hospital administration.
|
1 year and 4 month to collect data.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pharmacovigilance
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adverse Drug Reaction
-
Assiut UniversityNot yet recruitingAntiarrhythmic Drug Adverse Reaction
-
Population CouncilCompleted
-
Romanian Society of Anesthesia and Intensive CareUnknownGeneral Anesthetic Drug Adverse ReactionRomania
-
University Hospital Hradec KraloveCompletedGeneral Anesthetic Drug Adverse ReactionCzech Republic
-
Damanhour Teaching HospitalRecruitingGeneral Anesthetic Drug Adverse ReactionEgypt
-
Poznan University of Medical SciencesCompletedGeneral Anesthetic Drug Adverse ReactionPoland
-
Sun Yat-sen UniversityUnknownNon-steroidal Anti-inflammatory Drug Adverse ReactionChina
-
Assiut UniversityUnknownAntiviral Drug Adverse Reaction
-
Izmir Ataturk Training and Research HospitalNot yet recruitingPsychotropic Agents Causing Adverse Effects in Therapeutic Use | Anticholinergic Adverse Reaction | Anticholinergic Syndrome | Antiarrhythmic Drug Adverse Reaction | Antiparkinsonism Drugs Causing Adverse Effects in Therapeutic Use | Antispasmodic Adverse Reaction
-
Brigham and Women's HospitalNational Institutes of Health (NIH); Atrius HealthCompletedAging | Adverse Drug Event | Benzodiazepine Sedative Adverse Reaction | Anticholinergic Adverse ReactionUnited States